Publications

Journal for ImmunoTherapy of Cancer  |  Sep 22, 2023

BND-22, a first-in-class humanized ILT2 blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer  |  Sep 22, 2023

BND-22, a first-in-class humanized ILT2 blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer  |  Sep 22, 2023

BND-22, a first-in-class humanized ILT2 blocking antibody, promotes antitumor immunity and tumor regression

Journal for ImmunoTherapy of Cancer  |  Sep 22, 2023

BND-22, a first-in-class humanized ILT2 blocking antibody, promotes antitumor immunity and tumor regression